Focus: Universal Brain develops precision psychiatry platforms leveraging EEG wearables and AI to enable personalized treatment in neurology and psychiatry. The company is early-stage with a single Phase 1/2 neurofeedback program for depression.
Profile data last refreshed 37m ago · AI intelligence enriched 1w ago
Stable — net +2 jobs in 30d
2 added, 0 removed. Backfill posture.
Suitable only for mission-driven early-stage biotech professionals comfortable with technical risk, preclinical timelines, and equity-dependent compensation.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Universal Brain
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Universal Brain's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles